“Non-Burdensome” Cost-Effectiveness Trials Require Docs’ Help – McClellan
This article was originally published in The Gray Sheet
Executive Summary
The medical community can help CMS develop real-world data about the use of new medical technologies, agency Administrator Mark McClellan told an American Medical Association conference in Washington, D.C. March 30
You may also be interested in...
Post-FDA Evidence Needed To Inform Coverage Decisions – McClellan
Generating comparative effectiveness data is most realistic after FDA approval, but improved mechanisms are needed, according to CMS Administrator Mark McClellan
Post-FDA Evidence Needed To Inform Coverage Decisions – McClellan
Generating comparative effectiveness data is most realistic after FDA approval, but improved mechanisms are needed, according to CMS Administrator Mark McClellan
AHRQ Cost-Effectiveness Research Fund Provision Included In Medicare Bill
The Agency for Healthcare Research & Quality would develop a cost-effectiveness research agenda under the Medicare reform conference agreement